Skip to main content
. 2017 Feb 27;10(3):240–244. doi: 10.5005/jp-journals-10005-1443

Table 1: Evaluation of clinical failures

     No pathology      Presence of pain      Swelling      Sinus tract opening      Presence of mobility      Total     
Formocresol      17           1                18     
Pulpotec      17           1                18     
Mineral trioxide aggregate      18                          18     
Emdogain      15           1      2           18